<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2021.103015</article-id><article-id pub-id-type="publisher-id">PI-42532</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20210300000_56205774.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  PD-1抑制剂联用的研究进展
  Research Progress of PD-1 Inhibitor Combination
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>岳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>煜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国药科大学生命科学与技术学院，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>05</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>112</fpage><lpage>120</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   PD-1抑制剂在癌症治疗领域已获得了巨大的成功，但仍存在很多不足。PD-抑制剂与其他疗法联用是目前临床治疗的发展方向。本文从肿瘤表型分类的角度出发，系统性总结了PD-1抑制剂联用的分类，并介绍了对应的经典疗法。 PD-1 inhibitors have achieved great success in the field of cancer treatment, but there are still many shortcomings. Combination of PD-inhibitors with other therapies is the current development direction of clinical treatment. In this paper, we systematically summarize the classification of PD-1 inhibitor combination from the perspective of tumor phenotype classification and introduce the corresponding classical therapies. 
  
 
</p></abstract><kwd-group><kwd>PD-1抑制剂联用，肿瘤微环境，免疫抑制细胞, PD-1 Inhibitor Combination</kwd><kwd> Tumor Microenvironment</kwd><kwd> Immunosuppressive Cells</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>PD-1抑制剂在癌症治疗领域已获得了巨大的成功，但仍存在很多不足。PD-抑制剂与其他疗法联用是目前临床治疗的发展方向。本文从肿瘤表型分类的角度出发，系统性总结了PD-1抑制剂联用的分类，并介绍了对应的经典疗法。</p></sec><sec id="s2"><title>关键词</title><p>PD-1抑制剂联用，肿瘤微环境，免疫抑制细胞</p></sec><sec id="s3"><title>Research Progress of PD-1 Inhibitor Combination</title><p>Yue Chen, Yu Liu<sup>*</sup></p><p>School of Life Science and Technology, China Pharmaceutical University, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/6-1710266x4_hanspub.png" /></p><p>Received: Apr. 20<sup>th</sup>, 2021; accepted: May 15<sup>th</sup>, 2021; published: May 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/6-1710266x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>PD-1 inhibitors have achieved great success in the field of cancer treatment, but there are still many shortcomings. Combination of PD-inhibitors with other therapies is the current development direction of clinical treatment. In this paper, we systematically summarize the classification of PD-1 inhibitor combination from the perspective of tumor phenotype classification and introduce the corresponding classical therapies.</p><p>Keywords:PD-1 Inhibitor Combination, Tumor Microenvironment, Immunosuppressive Cells</p><disp-formula id="hanspub.42532-formula48"><graphic xlink:href="//html.hanspub.org/file/6-1710266x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1710266x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1710266x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2018年，诺贝尔生理学与医学奖被授予给Allison和Honjo，以表彰他们发现了PD-1和CTLA-4这两个免疫检查点。他们研究的证明：免疫系统中存在着一些“刹车”蛋白，作为负性的免疫调节受体，维持机体自身免疫耐受。肿瘤利用这种机制，使得肿瘤微环境(tumor microenvironment, TME)中的免疫细胞处于被抑制状态，从而逃脱免疫系统的监视 [<xref ref-type="bibr" rid="hanspub.42532-ref1">1</xref>]。</p><p>PD-1/PD-L1信号通路可以抑制T细胞的激活、增殖，诱导效应T细胞的凋亡 [<xref ref-type="bibr" rid="hanspub.42532-ref2">2</xref>] 从而避免T细胞杀伤肿瘤。同时PD-1/PD-L1信号通路可以抑制调节性T细胞的凋亡维持肿瘤内部免疫抑制的微环境 [<xref ref-type="bibr" rid="hanspub.42532-ref3">3</xref>]。</p><p>PD-1抑制剂可以恢复T细胞的功能，激活自身免疫系统杀伤肿瘤，所以在不同类型的肿瘤中都有治疗潜力。2020年，帕博利珠单抗获批治疗MSI/MSR (微卫星不稳定性/错配修复)缺陷的癌症，这是首个基于生物标志物分型而非癌症分型的治疗方案。此外，激活后的免疫系统会产生记忆性T细胞，在体内发挥长效的抗肿瘤效果。因此，PD-1抑制剂是一种广谱、长效的抗肿瘤药物。</p><p>但PD-1抑制剂也存在很多临床不足：患者对其整体响应率不高(25%左右) [<xref ref-type="bibr" rid="hanspub.42532-ref4">4</xref>]、肿瘤容易耐药 [<xref ref-type="bibr" rid="hanspub.42532-ref5">5</xref>]、药物的存在副作用 [<xref ref-type="bibr" rid="hanspub.42532-ref6">6</xref>] 及肿瘤可能发生超进展(hyperprogressive disease, HPD) [<xref ref-type="bibr" rid="hanspub.42532-ref7">7</xref>]。</p><p>除了药物疗效问题外，PD-1抑制剂还存在激烈的商业竞争。以帕博利珠单抗为例，最初进入中国时，其年治疗费用超过30万元(包含赠药)。但受国产药降价影响，其两年治疗花费目前已降至14万元(包含赠药)。目前全球已有6款PD-1抑制剂上市。预计2~3年内，全球将会有超过20款PD-1抗体上市，而在研项目超百个。</p><p>为提高抗PD-1单抗的疗效、规避激烈的商业竞争，临床开发的方向已从单药治疗转向联合治疗：早在2019年，PD-1/PD-L1联合治疗的临床试验数量已经超过单药治疗的3倍多。本文将系统性介绍抗PD-1单抗联用方案及其机制。</p></sec><sec id="s6"><title>2. 肿瘤的表型及PD-1抑制剂联用的分类</title><p>临床上，根据肿瘤中T细胞的浸润和免疫状态不同，我们将肿瘤分为三种表型，分别是：免疫沙漠型(immune deserts)、免疫排斥型(immune-excluded tumors)、炎性肿瘤(inflamed tumors)：</p><p>1. 免疫沙漠型肿瘤，其内外都没有T细胞，对PD-1抑制剂几乎无响应。肿瘤通过抑制抗原的释放和呈递，使得T细胞无法被招募。</p><p>2. 免疫排斥型肿瘤，其外部存在大量T细胞，但内部很少。肿瘤通过抑制T细胞的浸润，使得被招募的T细胞无法进入肿瘤。</p><p>3. 炎性肿瘤，其内部有大量T细胞浸润，对PD-1抑制剂的潜在响应效果最好。但肿瘤可以通过肿瘤微环境(tumor microenvironment, TME)中其他途径抑制T细胞的活化、增殖，使T细胞无法杀伤肿瘤；另外当T细胞处于持续的抗原刺激或者长期暴露于慢性炎症环境中时，会发生耗竭现象。此时，T细胞失去正常的免疫应答功能，导致了肿瘤的免疫逃逸。</p><p>因此PD-1抑制剂的联用大致可以分为四类：增强肿瘤抗原的释放和呈递、增强T细胞的肿瘤浸润、逆转肿瘤微环境的免疫抑制、增强T细胞的免疫应答。</p></sec><sec id="s7"><title>3. 增强肿瘤抗原的释放和呈递</title><p>对于免疫沙漠型肿瘤，联合疗法可以增强肿瘤抗原释放和呈递，提高PD-1抑制剂的响应率。</p><sec id="s7_1"><title>3.1. 与放化疗联用</title><p>放化疗是过去十年与PD-1抑制剂联用中占比最多的类型。局部的放化疗导致肿瘤的免疫原性细胞死亡(immunogenic cell death, ICD)，同时释放大量的肿瘤抗原。抗原的释放使得肿瘤被免疫系统识别，从而促进T细胞向肿瘤部位迁移和浸润。</p><p>此外，放化疗清除了肿瘤中的调节性T细胞(regulatory T cells, Treg)和骨髓来源的抑制细胞(myeloid-derived suppressor cells, MDSCs)，逆转了肿瘤的免疫抑制，帮助浸润的T细胞杀伤肿瘤。</p><p>除放化疗外，一些新技术也可以增强肿瘤抗原的释放与呈递：如肿瘤新抗原疫苗或者溶瘤病毒等。</p></sec><sec id="s7_2"><title>3.2. 与新技术联用</title><p>肿瘤新抗原是肿瘤组织内特异性地表达的抗原，所以具有很好的安全性 [<xref ref-type="bibr" rid="hanspub.42532-ref8">8</xref>]。一项使用DC作为疫苗形式的临床试验(NCT00683670)表明，其能有效地招募并激活CD8+ T细胞，同时诱导TCR扩增 [<xref ref-type="bibr" rid="hanspub.42532-ref9">9</xref>]。</p><p>溶瘤病毒可以特异性地在肿瘤细胞中复制，能够造成肿瘤细胞的ICD，激活机体的获得性免疫系统；同时溶瘤病毒能够引发损伤相关的分子模式(damage-associated molecular pattern, DAMPs)和病原相关的分子模式(Pathogen-associated molecular patterns, PAMPs)，激活机体的固有免疫。OncoMyx公司的一款基于兔痘病毒的溶瘤病毒与PD-1抑制剂联用具有很好的效果 [<xref ref-type="bibr" rid="hanspub.42532-ref10">10</xref>]。</p></sec><sec id="s7_3"><title>3.3. 利用肿瘤自身的呈递机制</title><p>肿瘤会通过多种途径下调自身抗原表达，降低自身免疫原性。所以除了使用外源性的放化疗或者疫苗等手段外，我们还可以增强肿瘤自身的抗原呈递机制。ERAP1全称是内质网氨肽酶1。在呈递过程中，胞内抗原首先会被ERAP1分解为小片段，再结合MHC分子。肿瘤会过表达ERAP1，使其自身抗原被过度“修剪”，降低抗原的免疫原性。动物模型结果表明，ERAP1抑制剂与PD-1抑制剂联用优于单药，具有很好的协同效果 [<xref ref-type="bibr" rid="hanspub.42532-ref11">11</xref>]。</p><p>除了“修剪”抗原，肿瘤也会下调表面MHC分子的表达，帮助自身免疫逃逸。PCSK9是调控血液胆固醇代谢的关键蛋白。但研究人员发现，PCSK9也能直接结合MHC I类分子，介导其在溶酶体中的降解，从而下调肿瘤表面MHC分子的表达。敲除PCSK9的小鼠，肿瘤生长明显减缓；而使用PCSK9抑制剂能上调肿瘤MHC I类分子表达量，从而增强PD-1抑制剂抗肿瘤效果 [<xref ref-type="bibr" rid="hanspub.42532-ref12">12</xref>]。</p></sec></sec><sec id="s8"><title>4. 增强T细胞肿瘤浸润</title><p>对于免疫排斥型肿瘤来说，PD-1抑制剂疗效不理想主要的原因是T细胞浸润不足。抗原呈递细胞将T细胞从淋巴结募集到肿瘤部位后，肿瘤会限制T细胞的浸润 [<xref ref-type="bibr" rid="hanspub.42532-ref13">13</xref>]，主要通过如下三种方法：</p><p>首先，肿瘤会下调某些关键趋化因子，从而影响T细胞向肿瘤内部的迁移；</p><p>其次，肿瘤会依靠成纤维细胞或者基质细胞形成质密的物理屏障来阻碍T细胞的浸润，这往往伴随着TGF-β的高表达；</p><p>最后，异常增生的肿瘤内部血管也会导致高渗、低氧、高间质压的TME的形成，使得T细胞浸润变得困难。</p><p>联用疗法也主要从这三个途径增强PD-1抑制剂在免疫排斥型肿瘤中的效果。</p><sec id="s8_1"><title>4.1. 肿瘤趋化因子</title><p>趋化因子可以促进淋巴细胞向特定部位运动，在肿瘤发生和发展过程中具有重要作用。其中，CXCL9、CXCL10和CCL5这三种趋化因子已被证实可以促进T细胞向肿瘤浸润。因而肿瘤会下调这三种趋化因子，避免被T细胞杀伤。使用表观遗传学药物可以增强它们的表达 [<xref ref-type="bibr" rid="hanspub.42532-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.42532-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42532-ref16">16</xref>]。将其联用后，具有改善现有PD-1抑制剂效果的潜力。</p><p>而CXCL12是T细胞浸润的抑制性的趋化因子。其由成纤维细胞分泌，能将T细胞诱导迁移至肿瘤外。对CXCL12进行抑制可以增强T细胞的浸润状态 [<xref ref-type="bibr" rid="hanspub.42532-ref17">17</xref>]，也是一个潜在的靶点。</p></sec><sec id="s8_2"><title>4.2. 肿瘤的“物理屏障”</title><p>免疫排斥型肿瘤往往会形成“坚固”的物理屏障，这同时伴随着转化生因子-β (Transforming growth factor beta, TGF-β)的高表达 [<xref ref-type="bibr" rid="hanspub.42532-ref18">18</xref>]。TGF-β对物理屏障的形成至关重要。其会促进成纤维细胞和基质细胞的增殖，帮助肿瘤形成质密的细胞外基质(extracellular matrix, ECM)的形成，同时维持肿瘤的高间质压力。研究证明，TGF-β抑制剂可以破坏肿瘤的物理屏障，帮助T细胞浸润 [<xref ref-type="bibr" rid="hanspub.42532-ref19">19</xref>]。临床上，TGF-β抑制剂与PD-1抑制剂联用能使肿瘤应答率显著提升 [<xref ref-type="bibr" rid="hanspub.42532-ref20">20</xref>]：在一项针对非错配修复的结肠癌中，联用组取得了33.3%的响应率，而单药几乎无响应(P &lt; 0.05)。</p></sec><sec id="s8_3"><title>4.3. 肿瘤血管正常化</title><p>在VEGF等因子驱动下，肿瘤的血管往往异常增生：形态上曲折膨胀、分布不均；功能上易渗漏，高组织间隙压，同时伴随着局部灌注不足、缺氧等问题。这阻碍了药物的递送和免疫细胞的浸润。Rakesh Jain等提出“血管正常化”(vascular normalization)理论 [<xref ref-type="bibr" rid="hanspub.42532-ref21">21</xref>]，即通过低剂量的抗血管生成药物，使肿瘤血管功能和形态上的正常化，改善药物的递送及细胞的浸润。</p><p>目前VEGF是与PD-1抑制剂联用最热门的靶点。临床上，Genentech将阿替利珠单抗和贝伐单抗联用，在晚期肝细胞癌治疗中取得良好的协同效果，是肝细胞癌治疗领域的重大突破 [<xref ref-type="bibr" rid="hanspub.42532-ref22">22</xref>]。在总体生存期及无进展生存期两项指标上，联用方案均显著优于索拉非尼，同时患者死亡风险降低了42% [<xref ref-type="bibr" rid="hanspub.42532-ref22">22</xref>]。在这之前，晚期肝细胞癌的一线治疗药物仅有索拉非尼和仑伐替尼两种。而前者盘踞一线疗法位置已经长达13年。</p></sec></sec><sec id="s9"><title>5. 逆转TME的免疫抑制</title><p>肿瘤与其所处的环境构成了一个完整的功能实体。TME是一个由免疫和炎症细胞，肿瘤相关的基质细胞，肿瘤周围的间质、血管、各种代谢产物和因子组成的复杂系统，在在肿瘤的发生、发展、转移过程中发挥了不可替代的作用。TME会通过多种途径抑制浸润的T细胞的功能，帮助肿瘤实现免疫逃逸，促进肿瘤的恶性发展。这里主要介绍TME中的肿瘤代谢产物及免疫抑制细胞两类。</p><sec id="s9_1"><title>5.1. 肿瘤代谢产物</title><p>与正常细胞不同，肿瘤细胞会发生能量代谢的重编程。这不仅可以促进肿瘤的快速生长，还可以竞争性耗竭营养物质从而抑制免疫细胞的生长，帮助肿瘤发生免疫逃逸。</p><p>腺苷是TME中一个关键的免疫调节分子：可以抑制正常免疫细胞的分化成熟，发挥免疫抑制作用 [<xref ref-type="bibr" rid="hanspub.42532-ref23">23</xref>]。同时腺苷还可以作用于内皮细胞，促进肿瘤血管形成，帮助肿瘤转移。CD39、CD73作为磷酸水解酶先后参与腺苷的产生。将抗CD73抗体与抗PD-1抗体联用，可以降低TME中腺苷浓度，逆转免疫抑制 [<xref ref-type="bibr" rid="hanspub.42532-ref24">24</xref>]。腺苷在免疫细胞上的信号受体A2aR和A2bR同样是热门的联用靶点。有研究发现IL-7可以阻断A2aR的信号通路，保护CD8+ T细胞 [<xref ref-type="bibr" rid="hanspub.42532-ref25">25</xref>]，同时解除Treg细胞的抑制作用 [<xref ref-type="bibr" rid="hanspub.42532-ref26">26</xref>]。</p></sec><sec id="s9_2"><title>5.2. 抑制性免疫细胞</title><p>肿瘤TME中存在大量的免疫抑制细胞，其中比较重要的是肿瘤相关巨噬细胞(Tumor-associated macrophages, TAM)和调节性T细胞(regulatory T cells, Treg)两种。</p><p>TAM分为M1、M2两类。M2型TAM具有广泛的促肿瘤作用：其高表达PD-L1并分泌免疫抑制性细胞因子；同时M2型TAM还可以促进其他免疫抑制细胞如Treg细胞的增殖、抑制DC的成熟。针对TAM的主要联用思路是通过重编程，将TAM的M2表型逆转为M1表型，例如：靶向CSF-1R靶点可以下调M2相关基因，增强M1表达 [<xref ref-type="bibr" rid="hanspub.42532-ref27">27</xref>]；有研究人员发现二甲双胍可以通过AMPK-NF-κB信号通路逆转M2为M1型巨噬细胞，增强PD-1抑制剂效果 [<xref ref-type="bibr" rid="hanspub.42532-ref28">28</xref>]。</p><p>Treg是目前关注度最高的免疫抑制细胞，可以直接调控T细胞的功能：首先，Treg会耗竭TME中IL-2 (IL-2是T细胞生长因子)，抑制T细胞的活化与增殖；其次Treg高表达CTLA-4，同时会分泌抑制性细胞因子(TGF-β，IL-10和IL-35)，以帮助建立免疫抑制微环境 [<xref ref-type="bibr" rid="hanspub.42532-ref29">29</xref>]。最后，Treg细胞可以分泌穿孔素和颗粒酶，直接杀伤APC或者效应T细胞 [<xref ref-type="bibr" rid="hanspub.42532-ref30">30</xref>]。</p><p>此外Treg也表达PD-1，所以PD-1抑制剂也会解除Treg的受抑制状态 [<xref ref-type="bibr" rid="hanspub.42532-ref31">31</xref>]，使其发挥免疫抑制作用。因此当TME中Treg细胞比例过高时，使用PD-1抑制剂并不能激活T细胞。因此特异性清除TME中的Treg细胞，对提高PD-1抑制剂疗效具有重大意义。</p><p>上文提到，Treg会竞争性耗竭TME中的IL-2，是因为其高表达CD25。CD25是IL-2受体α亚基。它的存在使得Treg细胞对IL-2的亲和力相较于正常T细胞提高了100倍。罗氏早期研发中心开发出一款CD25非阻断性的抗体，可以结合并通过ADCC效应裂解Treg细胞。同时由于该抗体并不阻断CD25结合IL-2，所以不会对少量表达CD25的正常T细胞产生影响 [<xref ref-type="bibr" rid="hanspub.42532-ref32">32</xref>]，可以特异性清除TME中的Treg。</p><p>除了CD25，TME中大量存在的乳酸也是特异性清除Treg的一个重要靶点。Treg细胞为了适应肿瘤微环境，会提高对乳酸的代谢 [<xref ref-type="bibr" rid="hanspub.42532-ref33">33</xref>]。MCT1是Treg细胞表面的乳酸转运蛋白。Treg细胞通过MCT1蛋白摄入乳酸，获取能量。动物模型中，将MCT1抑制剂与PD-1抑制剂联用后，小鼠肿瘤显著消退，响应率也有提升 [<xref ref-type="bibr" rid="hanspub.42532-ref34">34</xref>]。另外研究人员发现CD36可以通过PPAR-β途径调整线粒体，使其适应TME中高浓度的乳酸环境。动物模型中，敲除CD36不会影响动物健康，同时能增强PD-1抑制剂效果 [<xref ref-type="bibr" rid="hanspub.42532-ref35">35</xref>]。</p></sec></sec><sec id="s10"><title>6. 增强T细胞的免疫应答</title><p>在长期抗原暴露或者炎性反应后，T细胞往往会耗竭或者失能。此时仅仅逆转TME中的免疫抑制已不足以恢复T细胞功能。耗竭性T细胞的特点是表面抑制性受体高表达。通过协同阻断其他抑制性受体、激活共刺激受体或者联用具有免疫调节功能的细胞因子都增强T细胞功能。</p><sec id="s10_1"><title>6.1. 与免疫检查点抑制剂联用</title><p>免疫检查点抑制剂靶点包括：CTLA-4、LAG-3、TIM-3、TIGIT等。</p><p>CTLA-4是最常见的免疫检查点联用靶点。虽然CTLA-4也是免疫检查点，但临床上发现抗CTLA-4抗体最主要作用机制是通过结合TME中的Treg细胞并通过Fc介导其清除 [<xref ref-type="bibr" rid="hanspub.42532-ref36">36</xref>]，因而可以逆转Treg对T细胞的免疫抑制作用，提高PD-1抑制剂的响应率。目前该联用方案已经获批治疗黑色素瘤、肾细胞癌和结直肠癌 [<xref ref-type="bibr" rid="hanspub.42532-ref37">37</xref>]。</p><p>LAG-3在TME中多数淋巴细胞上表达，也具有与PD-1联用的潜力，并且可能成为PD-1和CTLA-4后获批上市的第三个免疫检查点。LAG-3可促进Treg分化增殖，并抑制NKT、DC、CD4+ T细胞等的功能。T细胞上的LAG-3与PD-1协同抑制TCR信号 [<xref ref-type="bibr" rid="hanspub.42532-ref38">38</xref>]。目前，BMS已经披露了Nivolumab (抗PD-1单抗)和Relatlimab (抗LAG-3单抗)联用的三期临床数据(NCT03704077)：黑色素瘤患者无进展生存期得到明显改善。</p><p>TIM-3在PD-1耐药患者肿瘤中高表达。其与PD-1抑制剂联用可以更好促进肿瘤消退 [<xref ref-type="bibr" rid="hanspub.42532-ref39">39</xref>]。但TIM-3存在多个配体，因而TIM-3抑制剂的开发难度较大 [<xref ref-type="bibr" rid="hanspub.42532-ref40">40</xref>]。</p><p>TIGIT可以抑制肿瘤抗原的释放和呈递 [<xref ref-type="bibr" rid="hanspub.42532-ref41">41</xref>]。TIGIT与PD-1抑制剂联用后可显著延长小鼠的生存期 [<xref ref-type="bibr" rid="hanspub.42532-ref42">42</xref>]。目前，罗氏的替瑞利尤单抗(抗TIGIT抗体)和阿特珠单抗(抗PD-L1抗体) 联用方案已经被FDA授予突破性疗法，用于治疗一线转移性非小细胞肺癌。一项三期临床也处于开展中(NCT04294810)。</p></sec><sec id="s10_2"><title>6.2. 与免疫检查点激动剂联用</title><p>大量临床前研究表明，免疫检查点激动剂(4-1BB, OX40, ICOS, CD27, GITR)可以促进T细胞激活、增殖。但其单用的临床效果不佳：往往具有很强的毒性，同时响应率较低 [<xref ref-type="bibr" rid="hanspub.42532-ref43">43</xref>]，目前尚未有免疫检查点激动剂获批上市。所以将免疫检查点激动剂与PD-1抑制剂联用是热门的临床推进方向。其中比较重要的联用靶点是4-1BB与OX40。</p><p>4-1BB (CD137)是TNF受体超家族的成员。T细胞激活后，4-1BB上调表达，并通过NF-κB和MAPK通路，延长T细胞的存活。但4-1BB激动剂单独给药效果并不佳，同时具有较大的毒性 [<xref ref-type="bibr" rid="hanspub.42532-ref44">44</xref>]。而与PD-1抑制剂的联用则显示出很好的协同作用：可以逆转CD8+ T耗竭，增强自体的肿瘤免疫 [<xref ref-type="bibr" rid="hanspub.42532-ref45">45</xref>]。</p><p>OX40是T细胞的共刺激因子，作用与4-1BB类似。此外OX40的共刺激可以抑制Treg的FOXP3基因，抑制Treg细胞的分化。动物模型中，OX40激动剂与抗PD-1抗体联用取得了很好的联用收益，可以逆转T细胞的耗竭 [<xref ref-type="bibr" rid="hanspub.42532-ref46">46</xref>]。</p></sec><sec id="s10_3"><title>6.3. 与细胞因子联用</title><p>除了免疫检查点外，TME中的细胞因子也是一种很重要的免疫调节靶点。白介素(IL-2、15、21)、生长因子(GM-CSF)、干扰素(IFN-α)和肿瘤坏死因子(TNF-α)都具有与PD-1抑制剂联用的潜力 [<xref ref-type="bibr" rid="hanspub.42532-ref47">47</xref>]。此外，中和一些免疫抑制因子(IL-6、IL-10)也能增强PD-1抑制剂的临床疗效。</p><p>IL-2是首个被用于临床治疗的肿瘤免疫药物，对T细胞的发育和扩增具有重要作用。但其治疗窗口窄、半衰期短。同时IL-2对Treg细胞有更高的亲和力，所以低剂量时会优先激活Treg，导致免疫抑制。而高剂量又具有很高的毒性，会引发致命性的血管渗漏 [<xref ref-type="bibr" rid="hanspub.42532-ref48">48</xref>]。有研究表明，IL-2与PD-1抑制剂联用使得小鼠肿瘤完全消退。临床研究也表明，IL-2和PD-1抑制剂联用可以提高响应率 [<xref ref-type="bibr" rid="hanspub.42532-ref49">49</xref>]。</p><p>IL-15和IL-21都具有与IL-2类似的效果。其中IL-15与PD-1抑制剂联用后患者生存率上升 [<xref ref-type="bibr" rid="hanspub.42532-ref50">50</xref>]。IL-21在动物模型中具有更好的抗肿瘤效果，但缺少临床数据支撑 [<xref ref-type="bibr" rid="hanspub.42532-ref51">51</xref>]。</p></sec></sec><sec id="s11"><title>7. PD-1抑制剂的展望</title><p>除肿瘤治疗外，PD-1抑制剂也被应用于其他疾病的治疗，如HIV和阿尔兹海默症：HIV病毒会上调T细胞表面的PD-1，导致其耗竭。将PD-1抑制剂和TIGIT抑制剂联用，可以逆转这种耗竭，增强免疫反应，促进HIV的清除 [<xref ref-type="bibr" rid="hanspub.42532-ref52">52</xref>]。在针对阿尔兹海默症的研究中，研究人员发现PD-1抑制剂可以募集巨噬细胞进入大脑，清除组织中的淀粉样β斑块，改善小鼠的认知反应 [<xref ref-type="bibr" rid="hanspub.42532-ref53">53</xref>]。这提示我们，PD-1靶点在肿瘤治疗之外，仍然具有巨大的应用潜力。</p><p>同时，随着临床治疗和研究的深入，我们对于PD-1的机制取得了更深入的认识。有研究表明，当肿瘤抗原的释放和呈递不足时，PD-1抑制剂的使用不但不能激活杀伤性T细胞，反而使其功能紊乱，杀死T细胞 [<xref ref-type="bibr" rid="hanspub.42532-ref54">54</xref>]；还有学者发现PD-1在肿瘤细胞上也广泛表达，且可以通过AKT和ERK1/2等信号通路抑制肿瘤生长。使用PD-1抑制剂后，解除了PD-1对肿瘤的抑制。若此时T细胞募集和活化水平较低，PD-1抑制剂反而可能导致肿瘤的超进展 [<xref ref-type="bibr" rid="hanspub.42532-ref55">55</xref>]。这提示我们PD-1抑制剂具有两重性。</p><p>联用疗法可以解决PD-1抑制剂在临床上遇到的很多不足，但往往也会增强毒副作用 [<xref ref-type="bibr" rid="hanspub.42532-ref56">56</xref>]。PD-1与CTLA-4的抑制剂联用后，患者的副作用发生率明显上升 [<xref ref-type="bibr" rid="hanspub.42532-ref57">57</xref>]；PD-1抑制剂与EGFR或者ALK抑制剂联用不仅效果不理想 [<xref ref-type="bibr" rid="hanspub.42532-ref58">58</xref>]，还可能出现严重副作用，导致患者死亡 [<xref ref-type="bibr" rid="hanspub.42532-ref59">59</xref>]。所以如何降低联用疗法的副作用，是目前研究的一个重点。有研究就是在PD-1、CTLA-4联用基础上，对TNF-α进行阻断，发现可以改善动物模型中炎症副作用，同时增强抗肿瘤效果 [<xref ref-type="bibr" rid="hanspub.42532-ref60">60</xref>]。</p></sec><sec id="s12"><title>8. 结语</title><p>PD-1抑制剂是肿瘤治疗领域的重大突破，已经获得了巨大的临床收益和商业成功，但也面临着商业竞争加剧及临床疗效不足两方面问题。这驱使着工业界和学术界通过联合疗法寻求突破。本文从肿瘤的不同表型出发，总结出PD-1联用的四种机制，并介绍了具有代表性的联用疗法。我们相信随着研究的深入，PD-1抑制剂会为更多的肿瘤患者带来帮助。</p></sec><sec id="s13"><title>文章引用</title><p>陈 岳,刘 煜. PD-1抑制剂联用的研究进展Research Progress of PD-1 Inhibitor Combination[J]. 药物资讯, 2021, 10(03): 112-120. https://doi.org/10.12677/PI.2021.103015</p></sec><sec id="s14"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42532-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ljunggren, H.G., Jonsson, R. and Höglund, P. (2018) Seminal Immunologic Discoveries with Direct Clinical Implica-tions: The 2018 Nobel Prize in Physiology or Medicine Honours Discoveries in Cancer Immunotherapy. Scandinavian Journal of Immunology, 88, e12731. &lt;br&gt;https://doi.org/10.1111/sji.12731</mixed-citation></ref><ref id="hanspub.42532-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. &lt;br&gt;https://doi.org/10.1111/j.1600-065X.2010.00923.x</mixed-citation></ref><ref id="hanspub.42532-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fife, B.T. and Pauken, K.E. (2011) The Role of the PD-1 Pathway in Autoimmunity and Peripheral Tolerance. Annals of the New York Academy of Sciences, 1217, 45-59. &lt;br&gt;https://doi.org/10.1111/j.1749-6632.2010.05919.x</mixed-citation></ref><ref id="hanspub.42532-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61.  
&lt;br&gt;https://doi.org/10.1126/science.aaa8172</mixed-citation></ref><ref id="hanspub.42532-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">严时佳, 孙蕾, 万国辉. PD-1/PD-L1免疫治疗在肿瘤中的耐药机制和研究进展[J]. 药学学报, 2019, 54(10): 1728-1734.</mixed-citation></ref><ref id="hanspub.42532-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">谢同济, 王守正, 邢镨元. 解析PD-1/PD-L1抑制剂分子结构差异与不良反应的相关性[J]. 中国肺癌杂志, 2020, 23(7): 603.</mixed-citation></ref><ref id="hanspub.42532-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wartewig, T., Kurgyis, Z., Keppler, S., et al. (2017) PD-1 Is a Haploinsufficient Suppressor of T Cell Lymphomagenesis. Nature, 552, 121-125. &lt;br&gt;https://doi.org/10.1038/nature24649</mixed-citation></ref><ref id="hanspub.42532-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Blass, E. and Ott, P.A. (2021) Advances in the Development of Person-alized Neoantigen-Based Therapeutic Cancer Vaccines. Nature Reviews Clinical Oncology, 18, 215-229.</mixed-citation></ref><ref id="hanspub.42532-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Carreno, B.M., Magrini, V., Becker-Hapak, M., et al. (2015) A Dendritic Cell Vaccine Increases the Breadth and Diversity of Melanoma Neoantigen-Specific T Cells. Science, 348, 803-808. &lt;br&gt;https://doi.org/10.1126/science.aaa3828</mixed-citation></ref><ref id="hanspub.42532-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rahman, M.M. and McFadden, G. (2020) Oncolytic Virotherapy with Myxoma Virus. Journal of Clinical Medicine, 9, 171. &lt;br&gt;https://doi.org/10.3390/jcm9010171</mixed-citation></ref><ref id="hanspub.42532-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Joyce, P., Young, L., Quibell, M., et al. (2020) 446 Immunopeptidome Changes Mediated by a Novel ERAP1 Inhibitor Leads to Tumor Growth Inhibition. Journal for ImmunoTherapy of Cancer, 8, A472.  
&lt;br&gt;https://doi.org/10.1136/jitc-2020-SITC2020.0446</mixed-citation></ref><ref id="hanspub.42532-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Bao, X., Hu, M., et al. (2020) Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature, 588, 693-698. &lt;br&gt;https://doi.org/10.1038/s41586-020-2911-7</mixed-citation></ref><ref id="hanspub.42532-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Endres, S. and Kobold, S. (2019) Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy. Immunotherapy, 11, 201-213. &lt;br&gt;https://doi.org/10.2217/imt-2018-0111</mixed-citation></ref><ref id="hanspub.42532-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Peng, D., Kryczek, I., Nagarsheth, N., et al. (2015) Epigenetic Silenc-ing of TH 1-Type Chemokines Shapes Tumour Immunity and Immunotherapy. Nature, 527, 249-253. &lt;br&gt;https://doi.org/10.1038/nature15520</mixed-citation></ref><ref id="hanspub.42532-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Nagarsheth, N., Peng, D., Kryczek, I., et al. (2016) PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Research, 76, 275-282.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-15-1938</mixed-citation></ref><ref id="hanspub.42532-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Topper, M.J., Vaz, M., Chiappinelli, K.B., et al. (2017) Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell, 171, 1284-1300.e21. &lt;br&gt;https://doi.org/10.1016/j.cell.2017.10.022</mixed-citation></ref><ref id="hanspub.42532-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mortezaee, K. (2020) CXCL12/CXCR4 Axis in the Microenvironment of Solid Tumors: A Critical Mediator of Metastasis. Life Sciences, 249, Article ID: 117534. &lt;br&gt;https://doi.org/10.1016/j.lfs.2020.117534</mixed-citation></ref><ref id="hanspub.42532-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tauriello, D.V.F., Palomo-Ponce, S., Stork, D., et al. (2018) TGFβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis. Nature, 554, 538-543. &lt;br&gt;https://doi.org/10.1038/nature25492</mixed-citation></ref><ref id="hanspub.42532-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mariathasan, S., Turley, S.J., Nickles, D., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548. &lt;br&gt;https://doi.org/10.1038/nature25501</mixed-citation></ref><ref id="hanspub.42532-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kim, H.S., Ahn, J.H., Kim, J.E., et al. (2020) A Phase I Study of TGF-β Inhibitor, Vactosertib in Combination with Imatinib in Patients with Advanced Desmoid Tumor (Aggressive Fibromato-sis). Journal of Clinical Oncology, 38, 11557. &lt;br&gt;https://doi.org/10.1200/JCO.2020.38.15_suppl.11557</mixed-citation></ref><ref id="hanspub.42532-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y., Goel, S., Duda, D.G., et al. (2013) Vascular Normalization as an Emerging Strategy to Enhance Cancer Immuno-therapy. Cancer Research, 73, 2943-2948. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-12-4354</mixed-citation></ref><ref id="hanspub.42532-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. &lt;br&gt;https://doi.org/10.1056/NEJMoa1915745</mixed-citation></ref><ref id="hanspub.42532-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">万萍, 陈昊, 白爱平. 腺苷的免疫调节功能[J]. 世界华人消化杂志, 2014, 22(17): 2379-2384.</mixed-citation></ref><ref id="hanspub.42532-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Allard, B., Pommey, S., Smyth, M.J., et al. (2013) Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Re-search, 19, 5626-5635. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-13-0545</mixed-citation></ref><ref id="hanspub.42532-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Koyas, A., Tucer, S., Kayhan, M., et al. (2021) Interleukin-7 Protects CD8+ T Cells from Adenosine-Mediated Immunosuppression. Science Signaling, 14, eabb1269. &lt;br&gt;https://doi.org/10.1126/scisignal.abb1269</mixed-citation></ref><ref id="hanspub.42532-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Morello, A., Durand, J., Thepenier, V., et al. (2020) Ab-stract 910: A Novel Bifunctional anti-PD-1 IL-7 Fusion Protein to Reinvigorate Exhausted T Cell and Disarms Treg Suppressive Activity. Proceedings: AACR Annual Meeting 2020, Philadelphia, 27-28 April 2020 and 22-24 June 2020.</mixed-citation></ref><ref id="hanspub.42532-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Webb, M.W., Sun, J., Sheard, M.A., et al. (2018) Colony Stimulating Factor 1 Receptor Blockade Improves the Efficacy of Chemotherapy against Human Neuroblastoma in the Absence of T Lymphocytes. International Journal of Cancer, 143, 1483-1493. &lt;br&gt;https://doi.org/10.1002/ijc.31532</mixed-citation></ref><ref id="hanspub.42532-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wei, Z., Zhang, X., Yong, T., et al. (2021) Boost-ing Anti-PD-1 Therapy with Metformin-Loaded Macrophage-Derived Microparticles. Nature Communications, 12, 1-20. &lt;br&gt;https://doi.org/10.1038/s41467-020-20723-x</mixed-citation></ref><ref id="hanspub.42532-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cai, J., Wang, D., Zhang, G., et al. (2019) The Role of PD-1/PD-L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy. OncoTargets and Therapy, 12, 8437. &lt;br&gt;https://doi.org/10.2147/OTT.S221340</mixed-citation></ref><ref id="hanspub.42532-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Sakaguchi, S., Miyara, M., Costantino, C.M., et al. (2010) FOXP3+ Regulatory T Cells in the Human Immune System. Nature Reviews Immunology, 10, 490-500. &lt;br&gt;https://doi.org/10.1038/nri2785</mixed-citation></ref><ref id="hanspub.42532-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Aksoylar, H.I. and Boussiotis, V.A. (2020) PD-1+ Treg Cells: A Foe in Can-cer Immunotherapy? Nature Immunology, 21, 1311-1312. &lt;br&gt;https://doi.org/10.1038/s41590-020-0801-7</mixed-citation></ref><ref id="hanspub.42532-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Solomon, I., Amann, M., Goubier, A., et al. (2020) CD25-Treg-Depleting Antibodies Preserving IL-2 Signaling on Effector T Cells Enhance Effector Activation and Anti-tumor Immunity. Nature Cancer, 1, 1153-1166.  
&lt;br&gt;https://doi.org/10.1038/s43018-020-00133-0</mixed-citation></ref><ref id="hanspub.42532-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Franco, F. and Ho, P.C. (2017) Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. Trends in Cancer, 3, 583-592. &lt;br&gt;https://doi.org/10.1016/j.trecan.2017.06.005</mixed-citation></ref><ref id="hanspub.42532-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Watson, M.L.J., Vignali, P.D.A., Mullett, S.J., et al. (2021) Metabolic Support of Tumour-Infiltrating Regulatory T Cells by Lactic Acid. Nature, 591, 645-651.</mixed-citation></ref><ref id="hanspub.42532-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Franco, F., Tsui, Y.C., et al. (2020) CD36-Mediated Metabolic Adaptation Supports Regulatory T Cell Survival and Function in Tumors. Nature Immunology, 21, 298-308. &lt;br&gt;https://doi.org/10.1038/s41590-019-0589-5</mixed-citation></ref><ref id="hanspub.42532-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Du, X., Tang, F., Liu, M., et al. (2018) A Reappraisal of CTLA-4 Checkpoint Blockade in Cancer Immunotherapy. Cell Research, 28, 416-432. &lt;br&gt;https://doi.org/10.1038/s41422-018-0011-0</mixed-citation></ref><ref id="hanspub.42532-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Rotte, A. (2019) Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer. Journal of Experimental &amp; Clinical Cancer Research, 38, 255. &lt;br&gt;https://doi.org/10.1186/s13046-019-1259-z</mixed-citation></ref><ref id="hanspub.42532-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Long, L., Zhang, X., Chen, F., et al. (2018) The Promising Im-mune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy. Genes &amp; Cancer, 9, 176. &lt;br&gt;https://doi.org/10.18632/genesandcancer.180</mixed-citation></ref><ref id="hanspub.42532-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Das, M., Zhu, C. and Kuchroo, V.K. (2017) Tim-3 and Its Role in Regulating Anti-Tumor Immunity. Immunological Reviews, 276, 97-111. &lt;br&gt;https://doi.org/10.1111/imr.12520</mixed-citation></ref><ref id="hanspub.42532-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kuang, Z., Li, L., Zhang, P., et al. (2020) A Novel Antibody Targeting TIM-3 Resulting in Receptor Internalization for Cancer Immunotherapy. Antibody Therapeutics, 3, 227-236. &lt;br&gt;https://doi.org/10.1093/abt/tbaa022</mixed-citation></ref><ref id="hanspub.42532-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Manieri, N.A., Chiang, E.Y. and Grogan, J.L. (2017) TIGIT: A Key In-hibitor of the Cancer Immunity Cycle. Trends in Immunology, 38, 20-28. &lt;br&gt;https://doi.org/10.1016/j.it.2016.10.002</mixed-citation></ref><ref id="hanspub.42532-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Hung, A.L., Maxwell, R., Theodros, D., et al. (2018) TIGIT and PD-1 Dual Checkpoint Blockade Enhances Antitumor Immunity and Survival in GBM. Oncoimmunology, 7, e1466769. &lt;br&gt;https://doi.org/10.1080/2162402X.2018.1466769</mixed-citation></ref><ref id="hanspub.42532-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Garber, K. (2020) Immune Agonist Antibodies Face Critical Test. Nature Reviews Drug Discovery, 19, 3-5.  
&lt;br&gt;https://doi.org/10.1038/d41573-019-00214-5</mixed-citation></ref><ref id="hanspub.42532-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, L., Judkins, C., Hoare, J., et al. (2020) 812 Urelumab (Anti-CD137 Agonist) in Combination with Vaccine and Nivolumab Treatments Is Safe and Associated with Pathologic Response as Neoadjuvant and Adjuvant Therapy for Resectable Pancreatic Cancer. Journal for ImmunoTherapy of Can-cer, 8, A486-A487.  
&lt;br&gt;https://doi.org/10.1136/jitc-2020-SITC2020.0812</mixed-citation></ref><ref id="hanspub.42532-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Woroniecka, K.I., Rhodin, K.E., Dechant, C., et al. (2020) 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clinical Cancer Research, 26, 1349-1358.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-19-1068</mixed-citation></ref><ref id="hanspub.42532-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Messenheimer, D.J., et al. (2017) Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clinical Cancer Research, 23, 6165-6177.</mixed-citation></ref><ref id="hanspub.42532-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Rahimi Kalateh Shah Mohammad, G., Ghahremanloo, A., Soltani, A., et al. (2020) Cytokines as Po-tential Combination Agents with PD-1/PD-L1 Blockade for Cancer Treatment. Journal of Cellular Physiology, 235, 5449-5460.  
&lt;br&gt;https://doi.org/10.1002/jcp.29491</mixed-citation></ref><ref id="hanspub.42532-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Mullard, A. (2021) Restoring IL-2 to Its Cancer Immunotherapy Glory. Nature Reviews Drug Discovery, 20, 163-165.  
&lt;br&gt;https://doi.org/10.1038/d41573-021-00034-6</mixed-citation></ref><ref id="hanspub.42532-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">郭寒菲, 白日兰, 崔久嵬. 肺癌免疫检查点抑制剂的联合治疗研究进展[J]. 中国肺癌杂志, 2020, 23(2): 101.</mixed-citation></ref><ref id="hanspub.42532-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Knudson, K.M., Hicks, K.C., Alter, S., et al. (2019) Mecha-nisms Involved in IL-15 Superagonist Enhancement of Anti-PD-L1 Therapy. Journal for Immunotherapy of Cancer, 7, Article No. 82.  
&lt;br&gt;https://doi.org/10.1186/s40425-019-0551-y</mixed-citation></ref><ref id="hanspub.42532-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Cong, Y., Jia, M., et al. (2021) Targeting IL-21 to Tu-mor-Reactive T Cells Enhances Memory T Cell Responses and Anti-PD-1 Antibody Therapy. Nature Communications, 12, 951. &lt;br&gt;https://doi.org/10.1038/s41467-021-21241-0</mixed-citation></ref><ref id="hanspub.42532-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Chew, G.M., Fujita, T., Webb, G.M., et al. (2016) TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 12, e1005349.</mixed-citation></ref><ref id="hanspub.42532-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Baruch, K., Deczkowska, A., Rosenzweig, N., et al. (2016) PD-1 Immune Checkpoint Blockade Reduces Pathology and Improves Memory in Mouse Models of Alzheimer’s Disease. Nature Medicine, 22, 135-137.  
&lt;br&gt;https://doi.org/10.1038/nm.4022</mixed-citation></ref><ref id="hanspub.42532-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Verma, V., Shrimali, R.K., Ahmad, S., et al. (2019) PD-1 Blockade in Sub-primed CD8 Cells Induces Dysfunctional PD-1+ CD38 HI Cells and Anti-PD-1 Resistance. Nature Immunology, 20, 1231-1243.  
&lt;br&gt;https://doi.org/10.1038/s41590-019-0441-y</mixed-citation></ref><ref id="hanspub.42532-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Yang, X., Zhang, C., et al. (2020) Tumor Cell-Intrinsic PD-1 Receptor Is a Tumor Suppressor and Mediates Resistance to PD-1 Blockade Therapy. Proceedings of the National Academy of Sciences, 117, 6640-6650.  
&lt;br&gt;https://doi.org/10.1073/pnas.1921445117</mixed-citation></ref><ref id="hanspub.42532-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Hayashi, H. and Nakagawa, K. (2020) Combination Therapy with PD-1 or PD-L1 Inhibitors for Cancer. International Journal of Clinical Oncology, 25, 818-830. &lt;br&gt;https://doi.org/10.1007/s10147-019-01548-1</mixed-citation></ref><ref id="hanspub.42532-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Boutros, C., Tarhini, A., Routier, E., et al. (2016) Safety Pro-files of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nature Reviews Clinical Oncology, 13, 473. &lt;br&gt;https://doi.org/10.1038/nrclinonc.2016.58</mixed-citation></ref><ref id="hanspub.42532-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Gainor, J.F., Shaw, A.T., Sequist, L.V., et al. (2016) EGFR Muta-tions and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 22, 4585-4593. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-15-3101</mixed-citation></ref><ref id="hanspub.42532-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Oshima, Y., Tanimoto, T., Yuji, K., et al. (2018) EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with Non-Small Cell Lung Cancer. JAMA Oncology, 4, 1112-1115.  
&lt;br&gt;https://doi.org/10.1001/jamaoncol.2017.4526</mixed-citation></ref><ref id="hanspub.42532-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Perez-Ruiz, E., Minute, L., Otano, I., et al. (2019) Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy. Nature, 569, 428-432. &lt;br&gt;https://doi.org/10.1038/s41586-019-1162-y</mixed-citation></ref></ref-list></back></article>